Comparative Pharmacology
Head-to-head clinical analysis: SULFADIAZINE SODIUM versus TRIPLE SULFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFADIAZINE SODIUM versus TRIPLE SULFA.
SULFADIAZINE SODIUM vs TRIPLE SULFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfadiazine is a competitive inhibitor of dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydropteroate, thereby inhibiting bacterial folic acid synthesis.
Inhibits bacterial dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR), blocking folate synthesis essential for nucleic acid production.
2-4 g IV initially, then 1-2 g IV every 6-8 hours; oral dose: 2-4 g loading, then 1-2 g every 6 hours
1 g orally every 12 hours for 10 days (as sulfadiazine, sulfamethazine, and sulfamerazine combination).
None Documented
None Documented
Terminal elimination half-life: 10-20 hours (prolonged in renal impairment; context: requires dose adjustment in CrCl <50 mL/min).
6-12 hours (sulfadiazine 10-13h, sulfamerazine 16-24h, sulfamethazine 7-12h); prolonged in renal impairment.
Renal: 60-85% (via glomerular filtration and tubular secretion, with acetylation in liver reducing solubility and increasing crystalluria risk). Biliary/fecal: less than 15%. Unchanged drug and acetylated metabolites both excreted.
80-90% renal (glomerular filtration and tubular secretion) as unchanged drug and acetylated metabolites; 5-10% biliary/fecal.
Category D/X
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic